EVGNNasdaqAgricultural ChemicalsFiscal year ends December 31
Evogene Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$0.37−0.02 (-4.71%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 0.3
- Dividend yield
- –
Evogene statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Agricultural Chemicals companies for comparison
Valuation
| Measure | Evogene | Industry median |
|---|---|---|
| Market Cap | $3.21M | $166.30M |
| Enterprise Value | $2.95M | $88.19M |
| PE Ratio | 0.34 | 20.44 |
| PS Ratio | 0.83 | 3.65 |
Enterprise value
| Measure | Evogene | Industry median |
|---|---|---|
| EV / Sales | 0.77 | 2.51 |
Income (trailing twelve months)
| Measure | Evogene | Industry median |
|---|---|---|
| Revenue | $3.85M | $58.34M |
| Gross Profit | -$241.00K | $105.94M |
| Operating Income | -$14.03M | -$21.40M |
| Pretax Income | -$13.50M | -$14.34M |
| Net Income | -$8.49M | -$22.46M |
| EBITDA | -$12.89M | -$16.91M |
| EPS (Diluted) | $1.08 | -$0.83 |
Margins
| Measure | Evogene | Industry median |
|---|---|---|
| Gross Margin | -6.25% | 52.9% |
| Operating Margin | -364.2% | -44.0% |
| Pretax Margin | -350.3% | -13.3% |
| Profit Margin | -220.2% | -40.2% |
| EBITDA Margin | -334.5% | -30.2% |
| FCF Margin | -353.9% | -9.27% |
Returns
| Measure | Evogene | Industry median |
|---|---|---|
| Return on Assets (ROA) | -35.8% | -40.9% |
| Return on Capital Employed (ROCE) | -135.0% | -38.1% |
Growth
| Measure | Evogene | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -30.9% | 5.96% |
| Revenue Growth (3Y CAGR) | 32.0% | 2.25% |
| Revenue Growth (5Y CAGR) | 29.9% | 6.48% |
Balance sheet
| Measure | Evogene | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $9.32M | $61.43M |
| Net Cash (Debt) | $9.32M | $15.35M |
| Net Cash Per Share | $1.07 | $0.66 |
| Equity (Book Value) | -$3.29M | $49.09M |
| Book Value Per Share | -$0.38 | $1.37 |
| Tangible Book Value | -$3.29M | $23.52M |
| Working Capital | $7.81M | $76.81M |
Financial position
| Measure | Evogene | Industry median |
|---|---|---|
| Current Ratio | 3.57 | 3.34 |
| Quick Ratio | 3.19 | 2.44 |
| Interest Coverage | -7.26 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Evogene | Industry median |
|---|---|---|
| Operating Cash Flow | -$13.50M | -$12.35M |
| Capital Expenditures | -$135.00K | -$1.08M |
| Free Cash Flow | -$13.64M | -$20.22M |
| FCF Per Share | -$1.56 | -$0.42 |
Efficiency
| Measure | Evogene | Industry median |
|---|---|---|
| Asset Turnover | 0.16 | 0.39 |
| Inventory Turnover | 4.00 | 2.70 |
| Revenue Per Employee | $49.40K | $404.87K |
| Profits Per Employee | -$108.78K | -$703.34K |
| Employee Count | 78 | 74 |
Dividends and yields
| Measure | Evogene | Industry median |
|---|---|---|
| Earnings Yield | -264.5% | -23.3% |
| FCF Yield | -425.1% | -8.72% |
Shares
| Measure | Evogene | Industry median |
|---|---|---|
| Shares Outstanding | 8,718,190 | 58,127,000 |
| Shares Change (YoY) | 38.2% | 10.9% |
| Float | 4,300,640 | 49,136,700 |
| Shares Held by Insiders | 50.7% | 11.6% |
Taxes
| Measure | Evogene | Industry median |
|---|---|---|
| Income Tax | $1.00K | $79.87K |
Scores
| Measure | Evogene | Industry median |
|---|---|---|
| Altman Z-Score | -32.44 | -0.22 |
| Piotroski F-Score | 3 | 4 |
| Beneish M-Score | -7.36 | -2.62 |
Calculated by StockData from Evogene's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.